LifeTech Scientific Corporation provided earnings guidance for the six months ended June 30, 2019. For the period, the company expects to record an increase ranging from 30% to 40% in net profit for the six months ended 30 June 2019 as compared to the corresponding period in 2018. Such significant increase in net profit was primarily due to an increase in the sales revenue of the Group, especially the substantial growth in the sales revenue generated from the structural heart diseases business of the Group and the Group's sales revenue generated from the overseas markets. Meanwhile, other income of the Group also recorded a year-on-year growth during the Reporting Period.